Wave Life Sciences (WVE) EBIAT (2016 - 2025)
Wave Life Sciences (WVE) has disclosed EBIAT for 11 consecutive years, with -$53.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 281.79% year-over-year to -$53.2 million, compared with a TTM value of -$204.4 million through Dec 2025, down 110.68%, and an annual FY2025 reading of -$204.4 million, down 110.68% over the prior year.
- EBIAT was -$53.2 million for Q4 2025 at Wave Life Sciences, up from -$53.9 million in the prior quarter.
- Across five years, EBIAT topped out at $29.3 million in Q4 2024 and bottomed at -$61.8 million in Q3 2024.
- Average EBIAT over 5 years is -$32.1 million, with a median of -$38.3 million recorded in 2021.
- Peak annual rise in EBIAT hit 279.7% in 2024, while the deepest fall reached 951.9% in 2024.
- Year by year, EBIAT stood at -$34.8 million in 2021, then decreased by 25.65% to -$43.7 million in 2022, then surged by 62.76% to -$16.3 million in 2023, then skyrocketed by 279.7% to $29.3 million in 2024, then plummeted by 281.79% to -$53.2 million in 2025.
- Business Quant data shows EBIAT for WVE at -$53.2 million in Q4 2025, -$53.9 million in Q3 2025, and -$50.5 million in Q2 2025.